SCHEMBL6079148

SCHEMBL6079148

Cc1ccc(C#N)c(OC(CCN(C)C(=O)OC(C)(C)C)C(F)(F)F)n1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.34
NOS2 P35228 3/20 0.34
HDAC1 Q13547 1/20 0.33
ALDH1A1 P00352 1/20 0.32
GLA P06280 1/20 0.32
PDK2 Q15119 1/20 0.32
CACNA1G O43497 1/20 0.31
CACNA1B Q00975 1/20 0.31
CACNA1C Q13936 1/20 0.31
AAK1 Q2M2I8 3/20 0.31
CTSK P43235 1/20 0.31
GBA1 P04062 1/20 0.31
CYP2D6 P10635 1/20 0.30
SLC6A2 P23975 1/20 0.30
TRPA1 O75762 1/20 0.30
PGR P06401 1/20 0.30
AR P10275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6078728 0.89 SLC6A4 (0.45) SLC6A4NOS2PDK2CACNA1GCACNA1B
SCHEMBL6078732 0.89 SLC6A4 (0.45) SLC6A4NOS2PDK2CACNA1GCACNA1B
SCHEMBL6079371 0.85 LMNA (0.36) SLC6A4NOS2ALDH1A1GLAPDK2
SCHEMBL6079361 0.85 LMNA (0.36) SLC6A4NOS2ALDH1A1GLAPDK2
SCHEMBL6079017 0.83 CACNA1G (0.31) ALDH1A1GLAPDK2CACNA1GCACNA1B
SCHEMBL6079011 0.83 CACNA1G (0.31) ALDH1A1GLAPDK2CACNA1GCACNA1B
SCHEMBL6082710 0.80 SLC6A4 (0.46) SLC6A4NOS2AAK1TRPA1PGR
SCHEMBL6077823 0.77 SLC6A4 (0.44) SLC6A4NOS2PDK2CACNA1GCACNA1B
SCHEMBL6079711 0.74 CYP2D6 (0.41) SLC6A4NOS2ALDH1A1GLACYP2D6
SCHEMBL6079031 0.74 SLC6A4 (0.41) SLC6A4NOS2HDAC1CYP2D6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119109-B2 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase ASTRAZENECA AB (SE) 2006-10-10 US disclosed
US-20040220234-A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase ASTRAZENECA AB (SE) 2004-11-04 US disclosed
EP-1421067-A1 HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE AstraZeneca AB (SE) 2004-05-26 EP disclosed
WO-2003011831-A1 HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE ASTRAZENECA AB (SE) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220234-A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase NOS3, NOS2, NOS1 SLC6A4 1543/4885NOS2 2/4885HDAC1 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.